



Cite this: *Dalton Trans.*, 2017, **46**, 10847

Received 9th June 2017,

Accepted 13th July 2017

DOI: 10.1039/c7dt02107k

rsc.li/dalton

Synthesis and evaluation of biological properties of ferrocenyl–podophyllotoxin conjugates†

Anna Wieczorek,^a Andrzej Błaż, ^b Anna Makal, ^c Błażej Rychlik ^{*b} and Damian Plażuk ^{*a}

Three types, esters, amides and 1,2,3-triazoles, of ferrocenyl–podophyllotoxin conjugates were synthesised, and their anticancer activity was evaluated. We observed that the most potent ferrocenyl derivatives were esters. Esters **15**, **16** and **17** acted in a similar way to podophyllotoxin, *i.e.* reduced the number of G1 phase cells and induced G2/M blockage, while esters **14** and **18** and amide **19** blocked cells in S phase in a similar manner to etoposide.

Introduction

Native Americans used mandrake (*Podophyllum peltatum*) as an emetic, cathartic and anthelmintic herb. It was also used to treat warts and other proliferative skin conditions. In 1946, King and Sullivan demonstrated that an alcoholic extract of mandrake roots and rhizomes (called podophyllin) has colchicine-like properties.¹ The active substance, podophyllotoxin (PPT) (Fig. 1), was further shown to compete for the colchicine-binding site of microtubules² and thus lead to G2/M blockage of the cell cycle. But the high systemic toxicity of PPT

prevents the using of this compound in cancer medicine. Therefore, a series of its semisynthetic derivatives, including etoposide and teniposide (Fig. 1), were developed, and these are currently used as chemotherapeutics. The mode of action of the aforementioned compounds differs from that of PPT – they are known to induce single- and double-strand DNA breaks leading to the accumulation of cells in S and G2 phases.³ The cellular target of etoposide and teniposide is topoisomerase II⁴ – an enzyme responsible for the relief of torsional stress that occurs during DNA transcription and replication.

The success of podophyllotoxin-based anticancer drugs in chemotherapy encouraged scientists to search for new derivatives of PPT as anticancer drug candidates. Its structure–activity relationship (SAR) indicated that lactone and benzo[*d*]1,3-dioxolane moieties play a crucial role in the anticancer activity of PPT. Therefore, most of the current modifications of the PPT structure focus on 4-hydroxy and 4'-methoxy moieties.⁵ Simple esterification of a 4-hydroxy moiety with acrylic acids⁶ leads to potent anti-multidrug resistance (MDR) agents. Other ester conjugates of podophyllotoxin exhibit promising anticancer properties, *e.g.* conjugates with norcantharidin,^{6a} 5-fluorouracil,⁷ and alkanoic acids.⁸ Some amide derivatives of PPT, *e.g.* the spermidine derivative,^{9,10} are currently under testing in phase 1 clinical trials. 1,2,3-Triazolyl¹¹ and 1,2,3,4-tetrazolyl¹² linkers have also been successfully used in the construction of promising new podophyllotoxin-based active anti-cancer compounds.

The success of cisplatin in the treatment of cancers initiated an intensive search for new metal-based compounds for use as potential antibiotic or cytostatic agents.¹³ To date, many chemically diverse ferrocenyl compounds with promising anti-cancer,¹⁴ anti-bacterial¹⁵ and anti-malarial¹⁶ activities have been synthesised. Very recently, Jaouen *et al.* described the synthesis of *O*-ferrocenoylpodophyllotoxin; however, they




Fig. 1 Structures of podophyllotoxin **1**, etoposide **2**, and teniposide **3**.

^aDepartment of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland. E-mail: damplaz@uni.lodz.pl; Fax: (+48)42 6786583; Tel: (+48)42 6355760

^bCytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, 141/143 Pomorska St., 90-236 Łódź, Poland. E-mail: brychlik@biol.uni.lodz.pl

^cUniversity of Warsaw, Biological and Chemical, Research Centre, ul. Żwirki i Wigury 101, 02-096 Warsaw, Poland

† Electronic supplementary information (ESI) available. CCDC 1552895. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7dt02107k




Fig. 2 General structures of ester (left), amide (middle), and 1,2,3-triazole (right) ferrocenyl-podophyllotoxin conjugates.

only studied the cytotoxic properties of this compound towards two breast cancer cell lines.¹⁷

Ferrocenyl derivatives and analogues of antimetabolic drugs are able to show novel and unexpected properties.^{14c,18} We have demonstrated that a ferrocenyl analogue of paclitaxel is more potent in terms of its antiproliferative activity than the mother compound.¹⁸ In addition, a ferrocenyl analogue of another mitotic spindle toxin (plinabulin) is not only highly active in multidrug resistant cells but directly inhibits MDR proteins.^{14c} The latter results encouraged us to study the effect of the ferrocenyl moiety on the antiproliferative activity of podophyllotoxin. Herein we describe the synthesis and study of the cytostatic and cytotoxic properties of a series of ferrocenyl derivatives of podophyllotoxin (Fig. 2) towards a set of human cell lines, including multidrug resistant cells obtained *via* a stepwise selection with widely used chemotherapeutics. In addition, we also studied the effects of the metallocene moiety on cell cycle progression and tubulin polymerization.

Results and discussion

Synthesis

In order to investigate the influence of the ferrocenyl moiety on the cytotoxic properties of **1**, three types of ferrocene-podophyllotoxin conjugates were synthesised starting from **1**, azido **4** and amino **5** derivatives of podophyllotoxin (Fig. 2). First, the reaction of **1** with sodium azide in trifluoroacetic acid at RT led to 4-azido-4-deoxy-4-epipodophyllotoxin **4** in 90% yield.¹⁹ Further reduction of the azido group by hydrogen in the presence of 10% of palladium on carbon in ethyl acetate at RT gave the corresponding 4-amino-4-deoxy-4-epipodophyllotoxin **5** in 85% yield (Scheme 1).²⁰


Ferrocenylalkanoic acids required for the synthesis of ester and amide conjugates were synthesised according to Scheme 2. 3-Ferrocenylpropionic acid **7**²¹ and 4-ferrocenylbutyric acid **8**²² were prepared in a Friedel-Crafts acylation of ferrocene with succinic and glutaric anhydride, respectively, while 5-ferrocenylpentanoic acid **10** was synthesised in two steps. First, ferrocene reacts with mono-methyl adipate and trifluoroacetic anhydride in the presence of triflic acid to give methyl 5-ferrocenylpentanoate **9**. Hydrolysis of the ester **9** with potassium hydroxide in aqueous solution led to the corresponding ketoacid **10**. Finally, reduction of the ketone group in **7**, **8** and **10** in a reaction with zinc amalgam and hydrochloric acid in a toluene solution led to ω -ferrocenylalkanoic acids **11**,²³ **12**²² and **13**,^{18b} respectively.

O-Acylation of **1** with ω -ferrocenylalkanoic acids and *N,N'*-diisopropylcarbodiimide (DIC) and 4-dimethylaminopyridine (DMAP) carried out in dichloromethane at RT for 24 h gave the corresponding esters **14–18** in 80–85% yields (Scheme 3).

Amide conjugates of podophyllotoxin were prepared in good yield in a reaction of **5** with ferrocenecarboxylic acid, 3-ferrocenylpropionic acid **7** and 4-ferrocenylbutyric acid **11** using BOP and DIPEA as coupling reagents. Reactions were carried out at RT in acetonitrile for 20 min and the corresponding amides **19–21** were isolated in 70%, 52%, and 72% yields, respectively (Scheme 4).



In order to synthesise 1,2,3-triazole conjugates of podophyllotoxin, first we prepared ω -alkynylferrocenes **26–28** *via* the Friedel-Crafts acylation of ferrocene with ω -alkynoic acids **22–24** in the presence of trifluoroacetic anhydride and triflic acid (Scheme 5).²⁴ Then, ethynylferrocene or **26–28** reacts with azide **4** in the presence of TTTA, copper(II) sulphate and sodium ascorbate in a mixture of methanol and water to give the corresponding 1,2,3-triazoles **29–32** in 86%, 75%, 32%, and 17% yields, respectively (Scheme 6).

The structure of compound **29** was confirmed by X-ray analysis. Crystals suitable for X-ray analysis were obtained by slow diffusion of *n*-pentane into a dichloromethane solution of **29**. Compound **29** crystallised in the chiral *P*₁ space group in a triclinic system. The cell unit comprises two independent molecules of compound **29** and two molecules of the solvent – dichloromethane. The crystal structure is chirally pure, with the following absolute configurations at the appropriate asymmetric carbon atoms: C13 (S), C14 (S), C17 (R), C18 (R), and analogously C53 (S), C54 (S), C57 (R), and C58 (R). The ORTEP representations of both molecules, with appropriate number-




Scheme 1 Synthesis of 4-azido- **4** and 4-amino-4-deoxy-4-epipodophyllotoxin **5**.




Scheme 2 Synthesis of η -ferrocenylalkanoic acids.

Scheme 3 Synthesis of podophyllotoxin esters 14–18.

Scheme 6 Synthesis of 1,2,3-triazoles 29–32.



Scheme 4 Synthesis of podophyllotoxin amides 19–21.

Scheme 5 Synthesis of η -alkynoylferrocenes 26–28.

ing, are presented in Fig. 3. As can be seen, X-ray analysis confirmed the inversion of the configuration of C-4 (here denoted as C13 and C53 in molecules A and B, accordingly) with respect to 1.

The two independent molecules of 29 share several structural features. In both molecules, the 1,2,3-triazole moiety is inclined approximately 20–30 degrees with respect to the cyclopentadienyl ring, with the C–H group pointing below the plane of the cyclopentadienyl ring. The planes of the 1,2,3-triazole ring, podophyllotoxin core and 3,4,5-trimethoxyphenyl moiety are almost perpendicular to one another. Structural differences between the two independent molecules are significant even if small, and manifest mostly in the following molecular fragments: (1) the terminal methoxy groups in the two molecules are rotated slightly differently with respect to the benzene ring they are connected to; and (2) the ferrocenyl moieties in the two molecules are slightly differently tilted with respect to the triazole ring; the effect is best visible in Fig. 4 (overlay of the two independent molecules): C2–C1–C11–N1: $-160.98(18)^\circ$, C42–C41–C51–N4: $-148.7(2)^\circ$; the ferrocenyl moiety in molecule B represents a conformation close to eclipsed, while in the case of molecule A the two cyclopentadienyl rings are significantly rotated with respect to each other: C41–Ct3–Ct4–C42: $-7.1(5)^\circ$, C1–Ct1–Ct2–C6: $-21.4(5)^\circ$; the C22 methylene






Fig. 3 ORTEP representations of molecules A (a) and B (b) of **29**. Atomic displacement parameters are presented at the 50% probability level. Hydrogen atom labels are omitted for clarity. Atomic numbers for molecule B are those from molecule A + 40. Most relevant bond lengths in Å and angles in °: Molecule A, C1–C11 1.463(3), C11–C12 1.375(2), C12–N3 1.354(2), N3–C13 1.475(2), C25–C13 1.520(3), average C–C distance in Fc: 1.424(6), average Fe–C distance in Fc: 2.044(4); C2–C1–C11–N1 –161.0(2), N2–N3–C13–C14 82.4(2); molecule B, C41–C51 1.460(3), C51–C52 1.382(3), C52–N6 1.351(3), N6–C53 1.478(3), C65–C53 1.519(3), C42–C41–C51–N4 –148.7(2), N5–N6–C53–C54 79.3(2).




Fig. 4 An overlay of the two molecules from the crystal structure of **29** (RMSD of mol. A and mol. B: 0.2556), molecule A is presented in red, and molecule B in blue.

group in molecule A is almost co-planar with the adjacent aromatic ring; the C22 atom shows a relatively elongated atomic displacement ellipsoid, which suggests possible slight disorder of the methylene, with alternative positions pointing either towards the ferrocenyl moiety or the 3,4,5-trimethoxyphenyl moiety. In contrast, the analogous C62 methylene group in molecule B is decidedly puckered towards the ferrocenyl moiety.

Cytotoxic activity

The cytotoxic activity of the investigated podophyllotoxin analogues was studied in a set of cell lines derived from human tumours of different tissue origin: colorectal adenocarcinomas Colo 205, HCT 116 and SW620, alveolar basal epithelial cell adenocarcinoma A549, hepatocellular carcinoma Hep G2 and breast adenocarcinoma MCF7. Additionally, we employed a panel of five MDR cell lines derived from SW620 which over-express various ABC proteins, namely ABCG2 (SW620C line), ABCC1 (SW620M and SW620E lines) and ABCB1 (SW620D, SW620E, and SW620 V lines).²⁵

None of the analysed substances were more active than podophyllotoxin (IC₅₀ values of PPT were always below 10 nM;

except for Colo 205, where cell survival dropped to 60% at 10 nM and remained constant up to 30 µM, results not shown); however, they were more toxic than etoposide. The most active of the newly synthesised compounds, however, were the esters **16** and **17** with a ferrocenyl moiety (IC₅₀ in the range between 0.11 and 0.68 µM; Table 1), followed by **15**, **18** and **14**. Amides **19–21** were poorly toxic, while of the four 1,2,3-triazoles only **31** and **32** exerted any biological effects in the micromolar range. None of the basic cell lines studied were specifically prone to the action of the compounds tested.

MDR cells seemed not to be significantly more resistant than the parental cell line to the investigated substances (Table 2). The SW620E cell line was originally obtained *via* a stepwise selection with etoposide and was roughly 9 times more resistant to **2** than the parental cell line (IC₅₀ of 140 µM vs. 16 µM, assayed by MTT-reduction assay).²⁵ In the current experimental setup, the resistance ratio of SW620E towards etoposide is slightly lower (the resistance factor value is approx. 7), but we employed a different viability assay here (neutral red uptake). Both parental and etoposide-resistant cells seem to be comparably sensitive to **14**, **17**, **18**, **31** and **32**, while the resistance ratio to **15** and **16** is between 2 and 3. All other MDR cell lines are as susceptible to ferrocenyl-podophyllotoxins conjugates as the parental cell line.

Cell cycle effects

Podophyllotoxin is a potent disruptor of microtubules and thus it prevents cells from completing cell division. Therefore, we studied the effects exerted by ferrocenyl-podophyllotoxins conjugates on SW620 and SW620E cells (Fig. 5). Esters **15**, **16** and **17** act in a way similar to podophyllotoxin, reducing the number of G1 phase cells and inducing G2/M blockage. On the other hand, esters **14**, **18**, and amide **19** tend to block cells in the S phase in a similar manner to etoposide **2** (although this effect is not pronounced). Such an outcome is clearly manifested in parental cells; however, the rate of G2/M blocked cells is also slightly increased in the SW620E line exposed to **15**, **16** and **17**.




Table 1 Cytotoxicity of ferrocenyl–podophyllotoxin conjugates towards a set of different cell lines, as determined by the neutral red uptake assay. 95% confidence intervals are given below (please note that due to the log-transformation of the data required to perform IC₅₀ calculations, these are asymmetrical). IC₅₀ values (expressed in μ M) were calculated based on three independent experiments. N.D. denotes a situation in which IC₅₀ values could not be determined (<50% viability was not achieved in the concentration range used)

Compound	Colo 205	HCT 116	SW620	A549	Hep G2	MCF7
1	N.D.	<0.001	0.002	0.005	0.002	<0.001
2	2.6	—	0.000–0.008	0.003–0.008	0.001–0.004	—
14	0.76–9.1	9	0.45	6	1.0	0.49
15	3.4	2–41	0.33–0.62	1–57	0.58–1.9	0.35–0.68
16	0.77–15.4	0.98	1.1	2.8	2.0	0.79
17	1.4	0.74–1.3	0.96–1.2	1.2–6.4	1.7–2.3	0.63–0.99
18	0.92–2.2	0.21	0.35	0.62	0.16	0.60
19	0.21	0.15–0.28	0.31–0.40	0.57–0.68	0.14–0.18	0.40–0.91
20	0.16–0.28	0.11	0.27	0.12	0.56	0.53
21	0.14	0.09–0.15	0.24–0.30	0.11–0.13	0.44–0.71	0.43–0.66
29	0.12–0.15	0.13	0.22	0.11	0.44	0.68
30	0.27	0.10–0.16	0.19–0.26	0.09–0.12	0.34–0.58	0.56–0.82
31	0.06–1.2	0.50	1.3	0.44	6.7	N.D.
32	58	0.40–0.63	1.1–1.6	0.23–0.65	3.9–11.3	N.D.
	6–588	N.D.	32	11.4	N.D.	0.08
	7.4	N.D.	3–394	8.0–16.1		0.01–0.63
	4.3–12.8	N.D.	N.D.	20.4	17.1	12.4
	N.D.	N.D.	N.D.	16.0–26.1	14.4–20.4	9.4–16.3
	N.D.	N.D.	N.D.	2.8	N.D.	N.D.
	N.D.	N.D.	N.D.	1.6–4.7	N.D.	N.D.
	N.D.	N.D.	N.D.	9.2	N.D.	N.D.
	N.D.	N.D.	N.D.	2.6–31.8		
	6.3	5.7	5.2	5.3	6.0	5
	4.6–8.7	4.4–7.4	2.1–12.6	2.9–9.8	3.9–9.2	1–43
	3.8	5.8	5.9	3.4	5.7	4.0
	3.1–4.6	4.4–7.4	4.8–7.2	2.1–5.6	4.6–7.2	3.0–5.3

Table 2 Cytotoxicity of ferrocenyl–podophyllotoxin conjugates towards a panel of multidrug resistant cell lines, as determined by the neutral red uptake assay. 95% confidence intervals are given below (please note that due to the log-transformation of the data required to perform IC₅₀ calculations, these are asymmetrical). IC₅₀ values (expressed in μ M) were calculated based on three independent experiments. N.D. denotes a situation in which IC₅₀ values could not be determined (<50% viability was not achieved in the concentration range used)

Compound	SW620	SW620C	SW620D	SW620E	SW620M	SW620V
1	0.002	0.005	0.003	0.009	<0.001	0.007
2	0.000–0.008	—	0.001–0.007	0.009–0.010	—	0.005–0.009
14	0.45	0.38	1.5	3.1	6.0	1.7
15	0.33–0.62	0.25–0.58	1.3–1.8	1.9–5.0	4.1–8.8	0.88–3.3
16	1.1	1.4	3.4	1.4	0.60	1.9
17	0.96–1.2	1.2–1.8	1.8–6.6	1.2–1.6	0.32–1.1	1.5–2.4
18	0.35	0.41	0.47	0.68	0.45	0.56
19	0.31–0.40	0.25–0.68	0.40–0.56	0.63–0.72	0.34–0.59	0.49–0.63
20	0.27	0.42	0.64	0.84	0.51	0.69
21	0.24–0.30	0.32–0.54	0.55–0.75	0.72–0.98	0.43–0.61	0.61–0.79
29	0.22	0.41	0.15	0.19	0.46	0.19
30	0.19–0.26	0.36–0.48	0.12–0.18	0.16–0.24	0.38–0.57	0.16–0.23
31	1.3	1.4	0.54	1.2	0.84	1.1
32	1.1–1.6	1.1–1.7	0.42–0.69	0.88–1.7	0.54–1.3	0.86–1.4
	32	N.D.	N.D.	33	N.D.	N.D.
	3–394			4–296		
	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
	N.D.	N.D.	N.D.	N.D.	5.6	16
	N.D.	N.D.	N.D.	N.D.	2.7–11.6	1–949
	N.D.	N.D.	N.D.	N.D.	5.2	8.2
	N.D.	N.D.	N.D.	N.D.	3.8–7.1	6.5–10.4
	5.2	8.6	4.8	9	4.6	25
	2.1–12.6	7.2–10.1	2.6–8.9	2–33	2.1–10.1	2–284
	5.9	9.5	4.1	6.1	5.3	10.9
	4.8–7.2	7.9–11.6	2.4–7.0	5.3–7.1	4.5–6.3	7.1–16.7






Fig. 5 Cell cycle phase distribution in SW620 (panel A) and SW620E (panel B) cells exposed to 10 nM of a given ferrocenylpodophyllotoxin for 48 h. Average data \pm SEM from 3 independent experiments. CTRL – cells incubated in a complete medium alone, DMSO – cells incubated in a complete medium with the addition of 0.1% dimethyl sulfoxide (solvent control).

Tubulin polymerization

In order to test whether the observed cell cycle disturbance results from direct interactions between ferrocenyl-podophyllotoxin conjugates and microtubules, we decided to investigate the tubulin polymerization rate. Tubulin subunits spontaneously polymerize at 37 °C and this process can be either augmented by taxol or attenuated by vincristine.²⁶ Therefore, we decided to employ both compounds as controls and studied the ability of newly synthesised organometallic podophyllotoxins to interfere with tubulin polymerization (Fig. 6).

We observed that only esters exerted notable inhibitory effects on tubulin polymerization (Table 3). The most active compounds were 15, 16 and 17, the latter one being as efficient as podophyllotoxin. These results are fully compliant with the cell cycle data.

Stability towards ester bond cleavage exhibited by esterases

Esterases are ubiquitous in the cell. Thus, one could argue that the biological effects observed for ferrocenyl esters of podophyllotoxin actually result from the action of podophyllotoxin which is released after the digestion of the ester bond. To verify this hypothesis, we incubated the esters with crude cell extract obtained by sonication of Hep G2 cells at pH 7.4. Sonication releases esterases from native cellular compart-

Table 3 IC₅₀ of active ferrocenylpodophyllotoxins towards tubulin polymerization (the mean and 95%-confidence intervals calculated for the data presented in Fig. 6)

Compound	IC ₅₀
Vincristine	0.57 (0.29–1.1)
1	0.43 (0.28–0.67)
2	No effect in the concentration range studied
14	19.7 (10.0–38.8)
15	1.6 (0.70–3.9)
16	1.4 (0.90–2.3)
17	0.49 (0.25–0.94)
18	27.1 (14.5–50.8)

ments resulting in the formation of a highly reactive enzymatic mixture. No protease inhibitors were added to avoid non-specific blockage of hydrolytic enzymes. None of the esters used in this study were cleaved to release PPT during a 2 hour incubation at 37 °C (Fig. S1†) while Oregon Green diacetate used as a positive control was completely hydrolysed within minutes. This result strongly suggests that the investigated podophyllotoxin esters are stable under biological conditions. Therefore, it may be implied that the ester form is actually their active form in the cells. Similar results are reported for other PPT esters, *e.g.* podophyllotoxin acetate, which are themselves believed to exert cytotoxic effects.^{8b}




Fig. 6 Effects of ferrocenyl-podophyllotoxin conjugates on the tubulin polymerization rate. CTRL – solvent control, PCL – paclitaxel, VINC – vincristine. Average data \pm SEM from 3 independent experiments.

Conclusions

We synthesised three series of ferrocenyl-podophyllotoxin conjugates: esters, amides and 1,2,3-triazoles. We found that the cytotoxic activity strongly depends on the type of linker between the metallocenyl and podophyllotoxin moieties. Of the compounds tested, only podophyllotoxin esters exerted significant biological effects on a number of cell lines, while amides and triazoles were significantly less cytotoxic. Their mechanism of action was similar to the action of the parental compound, as they efficiently disturbed tubulin polymerization leading to cell cycle inhibition. The synthesised compounds were also active towards multidrug resistant cells, including the etoposide-resistant SW620E cancer cell line, which makes them promising candidates for future research.



Experimental section

All reactions were conducted using standard Schlenk techniques under an argon atmosphere. Chemicals and solvents (HPLC grade) were purchased from Sigma-Aldrich and used as received. Dichloromethane (DCM) was distilled from calcium hydride, acetonitrile (ACN) was distilled from phosphorus pentoxide and stored over activated molecular sieves 4A (8–12 mesh). Melting points were determined on a capillary point DigiMelt MPA161 apparatus equipped with a digital thermometer and are uncorrected. UV-Vis spectra were recorded in a 1,2-dichloroethane solution using a Lambda 45 UV-Vis spectrometer (PerkinElmer) at 294 K. FT-IR spectra were recorded in KBr using a Nexus FT-IR spectrometer (Thermo Nicolet). ESI-MS spectra were recorded in positive mode on a Varian 500-MS LC ion trap spectrometer (samples were dissolved in methanol). Elemental analysis was performed for all new compounds. Unfortunately, we were not able to obtain correct results for all of the new compounds; however, inclusion of additional molecules of water for the calculation gave satisfying results. 1D (^1H , $^{13}\text{C}\{^1\text{H}\}$) and ^{13}C DEPT 135) and 2D (^1H - ^1H COSY, ^1H - ^{13}C HSQC or HMQC, ^1H - ^{13}C HMBC) NMR spectra were recorded on a Bruker ARX 600 MHz (spectrometer frequency 600.3 MHz for ^1H and 150.9 MHz for ^{13}C). Chemical shifts of the ^1H NMR spectra are referenced relative to residual protons in the deuterated solvent (CDCl_3 δ = 7.26 ppm for ^1H and δ = 77.00 ppm for $^{13}\text{C}\{^1\text{H}\}$; $\text{DMSO}-d_6$ δ = 2.50 ppm for ^1H and δ = 39.51 ppm for $^{13}\text{C}\{^1\text{H}\}$). Spectra were recorded at room temperature (301 K), chemical shifts are in ppm and coupling constants are in Hz. Thin-layer chromatography (TLC) was performed on aluminium sheets precoated with Merck 5735 Kieselgel 60F254. Column chromatography was carried out on FLUKA silica gel 60 for flash chromatography (0.040–0.063 mm, 230–400 mesh). The purity of all the compounds studied in biological assays was higher than 95%, as demonstrated by HPLC. HPLC analyses (for purity tests and the investigation of cellular esterase effects on ferrocenyl esters) were performed with a Shimadzu Prominence system equipped with a PDA detector, using a Phenomenex Kinetex 5 μ PFP 100 Å column (150 \times 4.6 mm). A gradient was applied using eluents A (0.1% TFA in ACN) and B (0.1% TFA in H_2O), starting from A:B = 30:70 to A:B = 90:10 within 20 min, then A:B = 90:10 for 10 min, and A:B = 30:70 for 10 min. Detection was recorded at wavelengths of 220 nm, 254 nm and 280 nm and a flow rate of 1 mL min $^{-1}$ was used.

Compounds **4**,¹⁹ **5**,²⁰ **7**,²¹ **8**,²² **11**,²³ **12**,²² **13**,^{18b} and **25–28**²⁴ were prepared according to the literature reported procedures. Compound **9**²⁸ was prepared according to the same procedure as that described for the synthesis of acetylferrocene²⁷ starting from mono-ethyl adipate. Compound **9** was hydrolysed with potassium hydroxide according to a literature reported procedure²⁸ to give the corresponding acid **10**.

General procedure A – synthesis of the esters 14–18

O-Ferrocenoylpodophyllotoxin 14. To a solution of 100 mg (0.241 mmol) of podophyllotoxin **1**, 14.7 mg (0.121 mmol) of

DMAP and 83 mg (0.362 mmol) of ferrocenecarboxylic acid in 4 cm 3 of anhydrous DCM was added 60.9 mg (75 μL , 0.483 mmol) of DIC and the resulting solution was stirred at RT for 24 h. Then, the solvent was evaporated to dryness and the pure product was obtained by column chromatography on silica (60 cm 3) using DCM/EtOAc (5/1) as an eluent. The pure product was obtained as orange crystals in 85% yield (129.6 mg). Mp 132.0–135.0 $^\circ\text{C}$ (dec.); elemental analysis found: C, 63.0; H, 5.1. $\text{C}_{33}\text{H}_{30}\text{FeO}_9$ requires C, 63.3; H, 4.8%; λ_{max} ($\text{ClCH}_2\text{CH}_2\text{Cl}$)/nm 448, 350 and 313 ($\epsilon/\text{dm}^3 \text{mol}^{-1} \text{cm}^{-1}$ 318, 690 and 1436); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 2933m, 2837m, 1780vs, 1709vs, 1588s, 1506vs, 1484vs, 1457vs, 1420s, 1376m, 1331m, 1267vs, 1239vs, 1171m, 1127vs, 1037s, 1001s, 932s, 870m, 826m, 775m, 485m; ESI-MS calculated for $\text{C}_{33}\text{H}_{30}\text{FeO}_9$ m/z = 626.1; found m/z 626.1 (M^+ , 100%), 627.1 ($\text{M} + \text{H}^+$, 41), 649.1 ($\text{M} + \text{Na}^+$, 70); R_f (HPLC) τ = 18.5 min. ^1H NMR (600 MHz, CDCl_3) δ 6.89 (1 H, s, H-5 or H-8), 6.58 (1 H, s, H-5 or H-8), 6.44 (2 H, s, H-2' and H-6'), 6.01 (1 H, d, J = 1.2 Hz, H-13) overlapped with 6.01 (1 H, d, J = 8.9 Hz, H-4), 5.99 (1 H, d, J = 1.2 Hz, H-13), 4.85 (1 H, br s, Cp), 4.82 (1 H, br s, Cp), 4.64 (1 H, d, J = 4.3 Hz, H-1), 4.49 (1 H, br s, Cp), 4.48 (1 H, br s, Cp), 4.46 (1 H, dd, J = 9.2, 7.0 Hz, H-11), 4.29 (1 H, t, J = 9.8 Hz, H-11), 4.26 (5 H, s, Cp), 3.81 (3 H, s, 4'-OCH $_3$), 3.80 (6 H, s, 2' and 5'-OCH $_3$), 2.97 (1 H, dt, J = 14.5, 4.4 Hz, H-2), 2.88–2.93 (1 H, m, H-3); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 173.7 (4-OCO); 172.4 (C-12); 152.7 (C $_{\text{Ph}}$); 148.2 (C $_{\text{Ph}}$); 147.7 (C $_{\text{Ph}}$); 137.4 (C $_{\text{Ph}}$); 134.9 (C $_{\text{Ph}}$); 132.4 (C $_{\text{Ph}}$); 128.8 (C $_{\text{Ph}}$), 109.8 (C-5 or C-8); 108.3 (C-2' and C-6'); 107.0 (C-5 or C-8); 101.6 (C-13); 90.1 (C $_{\text{ipso}}$), 73.4 (C-4); 71.9 (2 \times Cp); 71.6 (C-11); 70.3 (Cp); 70.2 (Cp); 69.8 (Cp); 60.8 (4'-OCH $_3$); 56.2 (3'-OCH $_3$ and 5'-OCH $_3$); 45.7 (C-2); 43.8 (C-1); 38.9 (C-3).

O-(4-Ferrocenylbutyryl)podophyllotoxin 15. This compound was synthesized in 86% yield (139 mg) according to general procedure A starting from 99 mg (0.362 mmol) of 4-ferrocenylbutyric acid. Mp 91.2–92.0 $^\circ\text{C}$; elemental analysis found: C, 64.7; H, 5.5. $\text{C}_{36}\text{H}_{36}\text{FeO}_9$ requires C, 64.7; H, 5.4%; λ_{max} ($\text{ClCH}_2\text{CH}_2\text{Cl}$)/nm 438, 363, 320 and 288 ($\epsilon/\text{dm}^3 \text{mol}^{-1} \text{cm}^{-1}$ 130, 159, 261 and 5769); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 2928m, 2837m, 1779s, 1732s, 1588m, 1506s, 1484s, 1457m, 1419m, 1379m, 1332m, 1291w, 1240vs, 1172m, 1127vs, 1076m, 1037s, 999s, 932m, 862m, 800m, 766m, 484m; ESI-MS calculated for $\text{C}_{36}\text{H}_{36}\text{FeO}_9$ m/z = 668.2; found m/z 668.2 (M^+ , 100%), 669.2 ($\text{M} + \text{H}^+$, 49), 691.2 ($\text{M} + \text{Na}^+$, 41); R_f (HPLC) τ = 20.5 min; ^1H NMR (600 MHz, CDCl_3) δ 6.75 (1 H, s, H-5 or H-8), 6.54 (1 H, s, H-5 or H-8), 6.39 (2 H, s, H-2' and H-6'), 5.99 (1 H, d, J = 1.1 Hz, H-13), 5.98 (1 H, d, J = 1.1 Hz, H-13), 5.88 (1 H, d, J = 9.2 Hz, H-4), 4.60 (1 H, d, J = 4.4 Hz, H-1), 4.36 (1 H, dd, J = 8.9, 7.3 Hz, H-11), 4.21–4.13 (10 H, m, Cp and H-11), 3.81 (3 H, s, 4'-OCH $_3$), 3.74 (6 H, s, 3' and 5'-OCH $_3$), 2.92 (1 H, dd, J = 14.5, 4.4 Hz, H-2), 2.84–2.78 (1 H, m, H-3), 2.48–2.39 (2 H, m, COCH $_2\text{CH}_2\text{CH}_2$), 2.36 (2 H, br s, COCH $_2\text{CH}_2\text{CH}_2$), 1.85 (2 H, br s, COCH $_2\text{CH}_2\text{CH}_2$); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 173.9 (4-OCO), 173.6 (C-12), 152.7 (C $_{\text{Ph}}$), 148.1 (C $_{\text{Ph}}$), 147.6 (C $_{\text{Ph}}$), 137.3 (C $_{\text{Ph}}$), 134.8 (C $_{\text{Ph}}$), 132.4 (C $_{\text{Ph}}$), 128.4 (C $_{\text{Ph}}$), 109.7 (C-5 or C-8), 108.2 (C-2' and C-6'), 107.0 (C-5 or C-8), 101.6 (C-13), 73.5 (C-4), 71.4 (C-11), 69.4 (Cp), 68.9 (Cp), 68.1 (Cp), 60.7



(4'-OCH₃), 56.2 (3' and 5'-OCH₃), 45.6 (C-2), 43.8 (C-1), 38.8 (C-3), 33.9 (COCH₂CH₂CH₂), 29.1 (COCH₂CH₂CH₂), 26.3 (COCH₂CH₂CH₂).

O-(3-Ferrocenylpropionyl)podophyllotoxin 16. This compound was synthesized in 82% yield (135 mg) according to general procedure A starting from 104 mg (0.362 mmol) of 3-ferrocenylpropionic acid. Mp 139.5–142.0 °C; elemental analysis found: C, 61.3; H, 5.4. C₃₆H₃₄FeO₁₀·H₂O requires C, 61.7; H, 5.2%; λ_{\max} (ClCH₂CH₂Cl)/nm 455, 364, 335 and 272 (ϵ /dm³ mol⁻¹ cm⁻¹ 439, 707, 1346 and 9197); IR (KBr) ν_{\max} /cm⁻¹: 3102w, 2922s, 2850m, 1779s, 1732s, 1667s, 1588m, 1506s, 1484s, 1457s, 1420m, 1379m, 1332m, 1240vs, 1156s, 1127vs, 1079m, 1037m, 998m, 930m, 867m, 766m, 481m; ESI-MS calculated for C₃₆H₃₄FeO₁₀ m/z = 682.1; found m/z 682.1 (M⁺, 54%), 683.1 (M + H⁺, 26), 705.1 (M + Na⁺, 100); R_f (HPLC) τ = 18.2 min; ¹H NMR (CDCl₃) δ = 6.91 (1 H, s, H-5 or H-8), 6.54 (1 H, s, H-5 or H-8), 6.41 (2 H, s, H-2' and H-6'), 6.00 (1 H, d, J = 1.3 Hz, H-13), 5.98 (1 H, d, J = 1.3 Hz, H-13), 5.97 (1 H, d, J = 8.7 Hz, H-4), 4.82 (2 H, br s, Cp), 4.61 (1 H, d, J = 2.9 Hz, H-1), 4.53 (2 H, br s, Cp), 4.46 (1 H, dd, J = 9.2, 6.4 Hz, H-11), 4.26 (5 H, s, Cp), 4.21–4.18 (1 H, m, H-11), 3.82 (3 H, s, 4'-OCH₃), 3.76 (6 H, s, 3' and 5'-OCH₃), 3.20–3.09 (2 H, m, COCH₂CH₂CO), 2.94–2.90 (2 H, m, H-2 and H-3), 2.80–2.69 (2 H, m, COCH₂CH₂CO); ¹³C{¹H} NMR (CDCl₃) δ 201.8 (FeCO), 173.8 (4-OCO and C-12), 152.7 (C_{Ph}), 148.1 (C_{Ph}), 147.6 (C_{Ph}), 137.3 (C_{Ph}), 134.9 (C_{Ph}), 132.3 (C_{Ph}), 128.5 (C_{Ph}), 109.7 (C-5 or C-8), 108.3 (C-2' and C-6'), 107.2 (C-5 or C-8), 101.5 (C-13), 78.2 (Cp_{ipso}), 73.7 (C-4), 72.4 (Cp), 71.5 (C-11), 70.0 (Cp), 69.2 (Cp), 60.7 (4'-OCH₃), 56.2 (3' and 5'-OCH₃), 45.6 (C-2), 43.8 (C-1), 38.7 (C-3), 34.3 (COCH₂CH₂CO), 28.1 (COCH₂CH₂CO).

O-(4-Ferrocenylbutyryl)podophyllotoxin 17. This compound was synthesized in 80% yield (134 mg) according to general procedure A starting from 109 mg (0.362 mmol) of 4-ferrocenylbutyric acid. Mp 102–103 °C; elemental analysis found: C, 63.5; H, 5.4. C₃₇H₃₆FeO₁₀ requires C, 63.8; H, 5.2%; λ_{\max} (ClCH₂CH₂Cl)/nm 455, 360 and 329 (ϵ /dm³ mol⁻¹ cm⁻¹ 473, 896 and 1626); IR (KBr) ν_{\max} /cm⁻¹: 3096w, 2932m, 2838m, 1779s, 1732s, 1665s, 1588s, 1506s, 1484s, 1456s, 1420s, 1379m, 1332m, 1240vs, 1127vs, 1037s, 1000s, 932m, 867m, 766m, 531m, 482m; ESI-MS calculated for C₃₇H₃₆FeO₁₀ m/z = 696.2; found m/z 696.2 (M⁺, 55%), 697.2 (M + H⁺, 28), 719.1 (M + Na⁺, 100); R_f (HPLC) τ = 18.2 min. ¹H NMR (CDCl₃) δ = 6.77 (1 H, s, H-5 or H-8), 6.53 (1 H, s, H-5 or H-8), 6.39 (2 H, s, H-2' and H-6'), 5.98 (1 H, d, J = 1.3 Hz, H-13), 5.97 (1 H, d, J = 1.3 Hz, H-13), 5.90 (1 H, d, J = 9.2 Hz, H-4), 4.78–4.77 (2 H, m, Cp), 4.60 (1 H, d, J = 4.4 Hz, H-1), 4.50–4.48 (2 H, m, Cp), 4.38 (1 H, dd, J = 9.2, 7.1 Hz, H-11), 4.20 (1 H, dd, J = 9.4, 1.0 Hz, H-11), 4.19 (5 H, s, Cp), 3.81 (3 H, s, 4'-OCH₃), 3.76 (6 H, s, 3' and 5'-OCH₃), 2.92 (1 H, dd, J = 14.5, 4.5 Hz, H-2), 2.87–2.80 (1 H, m, H-3), 2.77–2.75 (2 H, m, 4-OCOCH₂CH₂CH₂CH₂), 2.54–2.44 (2 H, m, 4-OCOCH₂CH₂CH₂CH₂), 1.79–1.78 (4 H, m, 4-OCOCH₂CH₂CH₂CH₂); ¹³C{¹H} NMR (CDCl₃) δ 203.6 (COFc), 173.8 (4-OCO), 173.6 (C-12), 152.7 (C_{Ph}), 148.1 (C_{Ph}), 147.6 (C_{Ph}), 137.3 (C_{Ph}), 134.8 (C_{Ph}), 132.4 (C_{Ph}), 128.4 (C_{Ph}), 109.7 (C-5 or C-8), 108.2 (C-2' and C-6'), 107.0 (C-5 or C-8), 101.6 (C-13), 79.0 (Cp_{ipso}), 73.6 (C-4), 72.2 (Cp), 71.4 (C-11), 69.8 (Cp),

69.3 (Cp), 60.7 (4'-OCH₃), 56.2 (3' and 5'-OCH₃), 45.6 (C-2), 43.8 (C-1), 39.0 (4-OCOCH₂CH₂CH₂CH₂), 38.8 (C-3), 34.3 (4-OCOCH₂CH₂CH₂CH₂), 24.8 (4-OCOCH₂CH₂CH₂CH₂), 23.7 (4-OCOCH₂CH₂CH₂CH₂).

O-(6-Ferrocenylhexanoyl)podophyllotoxin 18. This compound was synthesized in 81% yield (136 mg) according to general procedure A starting from 109 mg (0.362 mmol) of 6-ferrocenylhexanoic acid. Mp 156–157 °C; elemental analysis found: C, 63.5; H, 6.3. C₃₈H₄₀FeO₉·H₂O requires C, 63.9; H, 5.9%; λ_{\max} (ClCH₂CH₂Cl)/nm 435, 363 and 288 (ϵ /dm³ mol⁻¹ cm⁻¹ 109, 210 and 5043); IR (KBr) ν_{\max} /cm⁻¹: 3091w, 2922m, 2852m, 1766s, 1732s, 1587m, 1507m, 1484s, 1419m, 1375m, 1332m, 1240s, 1225s, 1191m, 1171m, 1128vs, 1031s, 992s, 926m; ESI-MS calculated for C₃₈H₄₀FeO₉ m/z = 696.2; found m/z 696.1 (M⁺); R_f (HPLC) τ = 21.6 min. ¹H NMR (CDCl₃) δ = 6.74 (1 H, s, H-5 or H-8), 6.54 (1 H, s, H-5 or H-8), 6.39 (2 H, s, H-2' and H-6'), 5.99 (1 H, d, J = 1.3 Hz, H-13), 5.97 (1 H, d, J = 1.2 Hz, H-13), 5.88 (1 H, d, J = 9.2 Hz, H-4), 4.60 (1 H, d, J = 4.4 Hz, H-1), 4.33 (1 H, dd, J = 9.1, 7.1 Hz, H-11), 4.20–4.08 (10 H, m, Cp and H-11), 3.82 (3 H, s, 4'-OCH₃), 3.76 (6 H, s, 3' and 5'-OCH₃), 2.91 (1 H, dd, J = 14.5, 4.5 Hz, H-2), 2.83–2.76 (1 H, m, H-3), 2.47–2.37 (2 H, m, (CH₂)₅), 2.28 (2 H, br s, (CH₂)₅), 1.71–1.66 (2 H, m, (CH₂)₅), 1.52–1.50 (2 H, m, (CH₂)₅), 1.42–1.35 (2 H, m, (CH₂)₅); ¹³C{¹H} NMR (CDCl₃) δ 174.1 (4-OCO), 173.6 (C-12), 152.7 (C_{Ph}), 148.1 (C_{Ph}), 147.6 (C_{Ph}), 137.3 (C_{Ph}), 134.8 (C_{Ph}), 132.4 (C_{Ph}), 128.4 (C_{Ph}), 109.7 (C-5 or C-8), 108.2 (C-2' and C-6'), 107.0 (C-5 or C-8), 101.6 (C-13), 73.4 (C-4), 71.4 (C-11), 69.1 (Cp), 68.7 (Cp), 67.7 (Cp), 60.7 (4'-OCH₃), 56.2 (3' and 5'-OCH₃), 45.6 (C-2), 43.8 (C-1), 38.8 (C-3), 34.3 (4-OCO(CH₂)₅), 30.7 (4-OCO(CH₂)₅), 29.4 (4-OCO(CH₂)₅), 28.9 (4-OCO(CH₂)₅), 24.9 (4-OCO(CH₂)₅).

General procedure B – synthesis of amides 19–21

4-Amino-4-deoxy-N-ferrocenyl-4-epipodophyllotoxin 19. To a mixture of 50 mg (0.121 mmol) of 4-amio-4-deoxy-4-epipodophyllotoxin 5, 30 mg (0.131 mmol) of ferrocenecarboxylic acid, 59 mg (0.133 mmol) of BOP in 5 ml of anhydrous acetonitrile was added 31 mg (42 μ l, 0.240 mmol) of DIPEA and the resulting solution was stirred at RT for 40 min. Then the solvent was evaporated to dryness and the crude product was purified by column chromatography on silica (50 ml) using a gradient of dichloromethane–methanol starting from 0 to 3% of methanol. Pure product was obtained as a yellow powder in 70% yield (53 mg). Mp 254–256 °C (dec.); elemental analysis found: C, 61.1; H, 5.6; N, 2.5. C₃₃H₃₁FeNO₈·1.5H₂O requires C, 60.8; H, 5.2; N, 2.2%; λ_{\max} (ClCH₂CH₂Cl)/nm 444, 345, 294 and 270 (ϵ /dm³ mol⁻¹ cm⁻¹ 263, 521, 5826 and 8627); IR (KBr) ν_{\max} /cm⁻¹: 3409s, 2919m, 1769s, 1648s, 1587m, 1503vs, 1482s, 1417m, 1391m, 1329m, 1290m, 1236s, 1188m, 1177m, 1127s, 1105m, 1033m, 999s, 926m, 862m, 826m, 481m; ESI-MS calculated for C₃₃H₃₁FeNO₈ m/z = 625.1; found m/z 626.1 (M + H⁺, 100%); R_f (HPLC) τ = 15.5 min. ¹H NMR (CDCl₃) δ = 6.79 (1 H, s, H-5 or H-8), 6.56 (1 H, s, H-5 or H-8), 6.31 (2 H, s, H-2' and H-6'), 5.99 (1 H, s, H-13), 5.98 (1 H, s, H-13), 5.74 (1 H, br s, CONH), 5.36 (1 H, br s, H-4), 4.75 (1 H, br s, Cp), 4.69 (1 H, br s, Cp), 4.62 (1 H, br s, H-1), 4.48 (1 H, t, J = 7.9 Hz, H-11), 4.44



(1 H, br s, Cp), 4.43 (1 H, br s, Cp), 4.28 (5 H, s, Cp), 3.93 (1 H, t, $J = 9.7$ Hz, H-11), 3.81 (3 H, s, 4'-OCH₃), 3.76 (6 H, s, 3'- and 5'-OCH₃), 3.01 (1 H, br s, H-3), 2.92 (1 H, br s, H-2); ¹³C{¹H} NMR (CDCl₃) δ 174.3 (C-12), 152.7 (C_{Ph}), 148.5 (C_{Ph}), 147.9 (C_{Ph}), 137.5 (C_{Ph}), 134.7 (C_{Ph}), 132.6 (C_{Ph}), 129.2 (C_{Ph}), 110.3 (C-5 or C-8), 108.9 (C = 5 or C-8), 108.4 (C-2' and C-6'), 101.7 (C-13), 71.4 (Cp), 70.2 (Cp), 69.2 (C-11), 68.6 (Cp), 60.7 (4'-OCH₃), 56.3 (3' and 5'-OCH₃), 48.2 (C-4), 43.9 (C-1), 42.0 (C-2), 37.5 (C-3).

4-Amino-4-deoxy-N-(3-ferrocenylpropionyl)-4-epipodophyllo-toxin 20. This compound was synthesized in 52% yield (43 mg) according to general procedure B starting from 37 mg (0.131 mmol) of 3-ferrocenylpropionic acid. Mp > 250 °C (dec.); elemental analysis found: C, 66.2; H, 5.5; N, 2.6. C₃₆H₃₅FeNO₉ requires C, 63.4; H, 5.2; N, 2.1%; λ_{max} (ClCH₂CH₂Cl)/nm 455, 361, 335 and 273 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 196, 414, 656 and 3766); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3423vs, 2923s, 2851m, 1773s, 1671s, 1654s, 1589m, 1507s, 1482s, 1459s, 1419m, 1396m, 1329m, 1263m, 1234s, 1190m, 1172m, 1125vs, 1089m, 1030m, 992m, 867m; ESI-MS calculated for C₃₆H₃₅FeNO₉ $m/z = 681.2$; found m/z 682.1 (M^+ , 100%); R_f (HPLC) $\tau = 15.5$ min; ¹H NMR (DMSO-d₆) δ 8.34 (1 H, d, $J = 8.5$ Hz, NH), 6.78 (1 H, s, H-5 or H-8), 6.54 (1 H, s, H-5 or H-8), 6.31 (2 H, s, H-2' and H-6'), 6.01 (1 H, s, H-13), 6.00 (1 H, s, H-13), 5.22 (1 H, dd, $J = 8.3$, 4.6 Hz, H-4), 4.83 (1 H, br s, Cp), 4.82 (1 H, br s, Cp), 4.57–4.56 (3 H, m, H-1 and Cp), 4.29 (5 H, s, Cp), 4.27 (1 H, t, $J = 8.1$ Hz, H-11), 3.90 (1 H, dd, $J = 10.5$, 8.9 Hz, H-11), 3.65 (6 H, s, 3' and 5'-OCH₃), 3.62 (3 H, s, 4'-OCH₃), 3.25 (1 H, dd, $J = 14.7$, 5.5 Hz, H-2), 3.13 (1 H, ddd, $J = 17.9$, 8.2, 5.3 Hz, 4-NHCOCH₂CH₂), 3.04–2.99 (1 H, m, 4-NHCOCH₂CH₂), 2.98–2.93 (1 H, m, H-3), 2.53–2.46 (1 H, m, 4-NHCOCH₂CH₂, overlapped with DMSO), 2.44–2.40 (1 H, m, 4-NHCOCH₂CH₂); ¹³C{¹H} NMR (DMSO-d₆) 202.2 (COFc), 174.4 (C-12), 171.4 (NHCO), 159.1 (C_{Ph}), 147.1 (C_{Ph}), 146.5 (C_{Ph}), 136.3 (C_{Ph}), 135.7 (C_{Ph}), 131.7 (C_{Ph}), 130.6 (C_{Ph}), 109.3 (C-5 or C-8), 109.1 (C-5 or C-8), 101.1 (C-2' and C-6'), 78.6 (Cp_{ipso}), 71.8 (Cp), 69.5 (Cp), 68.9 (Cp), 68.4 (C-13), 59.8 (4'-OCH₃), 55.7 (3' and 5'-OCH₃), 46.5 (C-4), 43.0 (C-1), 40.7 (C-2), 36.6 (C-3), 34.1 (4-NHCOCH₂CH₂), 28.6 (4-NHCOCH₂CH₂).

4-Dehydroxy-4-amino-N-(4-ferrocenylbutyryl)-4-epipodophyllo-toxin 21. This compound was synthesized in 72% yield (58 mg) according to general procedure B starting from 36 mg (0.131 mmol) of 4-ferrocenylbutyric acid. Mp 201–202 °C (dec.); elemental analysis found: C, 64.7; H, 6.2; N, 2.8. C₃₆H₃₇FeNO₈ requires C, 64.8; H, 5.6; N, 2.1%; λ_{max} (ClCH₂CH₂Cl)/nm 443, 364 and 320 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 103, 131 and 218); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3386m, 2932m, 1776s, 1671m, 1648m, 1589m, 1506vs, 1483vs, 1418m, 1390m, 1332m, 1288m, 1231vs, 1189m, 1161m, 1126vs, 1105s, 1037s, 1000s, 931m, 865m, 802m, 485m; ESI-MS calculated for C₃₆H₃₇FeNO₈ $m/z = 667.2$; found m/z 667.1 (M^+ , 100%), 668.1 ($M + H^+$, 58); R_f (HPLC) $\tau = 17.8$ min; ¹H NMR (DMSO-d₆) δ 8.23 (1 H, d, $J = 8.5$ Hz, NH), 6.79 (1 H, s, H-5 or H-8), 6.54 (1 H, s, H-5 or H-8), 6.30 (2 H, s, H-2' and H-6'), 6.01 (1 H, s, H-13), 5.99 (1 H, s, H-13), 5.24 (1 H, dd, $J = 8.4$, 4.7 Hz, H-4), 4.55 (1 H, d, $J = 5.3$ Hz, H-1), 4.33 (1 H, t, $J = 8.0$ Hz, H-11), 4.11 (5 H, s, Cp),

4.10–4.09 (1 H, m, Cp), 4.08–4.07 (1 H, m, Cp), 4.05–4.03 (2 H, m, Cp), 3.76 (1 H, dd, $J = 10.8$, 8.6 Hz, H-11), 3.65 (6 H, s, 3' and 5'-OCH₃), 3.62 (3 H, s, 4'-OCH₃), 3.23 (1 H, dd, $J = 14.5$, 5.4 Hz, H-2), 2.97–2.94 (1 H, m, H-3), 2.29 (2 H, dd, $J = 8.6$, 7.0 Hz, (CH₂)₃), 2.17 (2 H, dt, $J = 7.2$, 2.6 Hz, (CH₂)₃), 1.77–1.72 (2 H, m, (CH₂)₃); ¹³C{¹H} NMR (DMSO-d₆) 174.4 (C-12), 171.9 (4-NHCO), 152.0 (C_{Ph}), 147.1 (C_{Ph}), 146.6 (C_{Ph}), 136.4 (C_{Ph}), 135.7 (C_{Ph}), 131.7 (C_{Ph}), 130.8 (C_{Ph}), 109.3 (C-5 or C-8), 108.9 (C-5 or C-8), 108.2 (C-2' and C-6'), 101.2 (C-13), 88.2 (Cp_{ipso}), 68.3 (C-11), 68.2 (Cp), 67.7 (Cp), 66.8 (Cp), 59.8 (4'-OCH₃), 55.8 (3' and 5'-OCH₃), 46.4 (C-4), 43.0 (C-1), 40.7 (C-2), 36.4 (C-3), 34.9 ((CH₂)₃), 28.5 ((CH₂)₃), 26.6 ((CH₂)₃).

General procedure C – synthesis of 1,2,3-triazoles 29–32

4-Deoxy-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)-4-epipodophyllo-toxin 29. 100 mg (0.228 mmol) of 4-azido-4-deoxy-4-epipodophyllotoxin **4** and 46 mg (0.219) of ethynylferrocene were dissolved in 10 ml of methanol and 2 ml of water. To the resulting solution, a freshly prepared solution of 0.5 ml of 0.1 M CuSO₄ and 0.5 ml of 0.1 M sodium ascorbate and 0.23 ml of 0.01 M TTTA was added. After 20 h of stirring at RT, 50 ml of water was added and the product was extracted with ethyl acetate. The extract was washed twice with water and brine, dried and evaporated to dryness. Chromatography on silica using dichloromethane–ethyl acetate 85:15 as the eluent gave pure product in 86% yield (122 mg). Mp > 200 °C (dec.); elemental analysis found: C, 59.4; H, 5.1; N, 6.5. C₃₄H₃₁FeN₃O₇·2H₂O requires C, 59.6; H, 5.2; N, 6.1%; λ_{max} (ClCH₂CH₂Cl)/nm 412, 357 and 272 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 572, 1592 and 18 011); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 2911w, 2835w, 1781s, 1629m, 1588s, 1505s, 1484s, 1456m, 1418m, 1391m, 1332m, 1236vs, 1189m, 1158m, 1128vs, 1105s, 1037s, 1004s, 927m, 875m, 504m; ESI-MS calculated for C₃₄H₃₁FeN₃O₇ $m/z = 649.2$; found m/z 649.1 (M^+ , 100%); 650.1 ($M + H^+$, 73); R_f (HPLC) $\tau = 17.1$ min ¹H NMR (DMSO-d₆) 8.08 (1 H, s, H_{triazolyl}), 6.80 (1 H, s, H-5 or H-8), 6.72 (1 H, s, H-5 or H-8), 6.35 (2 H, s, H-2' and H-6'), 6.25 (1 H, d, $J = 5.4$ Hz, H-4), 6.03 (1 H, s, H-13), 6.02 (1 H, s, H-13), 4.76 (1 H, d, $J = 5.2$ Hz, H-1), 4.74 (1 H, s, Cp), 4.73 (1 H, s, Cp), 4.43 (1 H, t, $J = 8.0$ Hz, H-11), 4.31 (2 H, s, Cp), 4.01 (5 H, s, Cp), 3.69 (6 H, s, 3' and 5'-OCH₃), 3.65 (3 H, s, 4'-OCH₃), 3.57 (1 H, dd, $J = 14.7$, 5.2 Hz, H-2), 3.32–3.25 (1 H, m, H-3), 2.99 (1 H, dd, $J = 10.5$, 8.9 Hz, H-11). ¹³C{¹H} NMR (DMSO-d₆) 173.5 (C-12), 152.1 (C_{Ph}), 148.1 (C_{Ph}), 147.0 (C_{Ph}), 145.5 (C_{triazolyl}), 136.6 (C_{Ph}), 135.1 (C_{Ph}), 132.8 (C_{Ph}), 126.2 (C_{Ph}), 121.0 (CH_{triazolyl}), 109.8 (C-5 or C-8), 108.5 (C-5 or C-8), 108.2 (C-2' and C-6'), 101.5 (C-13), 75.4 (Cp_{ipso}), 69.2 (Cp), 68.3 (Cp), 67.2 (C-11), 66.3 (Cp), 59.9 (4'-OCH₃), 57.3 (C-4), 55.8 (3' and 5'-OCH₃), 43.0 (C-1), 40.8 (C-2), 36.5 (C-3).

4-Deoxy-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)-4-epipodophyllo-toxin 30. This compound was synthesized in 75% yield (111 mg) according to general procedure C starting from 52 mg (0.219 mmol) of propynylferrocene. Mp > 200 °C (dec.); elemental analysis found: C, 61.8; H, 5.2; N, 6.9. C₃₅H₃₁FeN₃O₈ requires C, 62.0; H, 4.6; N, 6.2%; λ_{max} (ClCH₂CH₂Cl)/nm 480 and 368 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 1158 and 2040); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3121w, 2930m, 2837w, 1782s,



1732w, 1628s, 1588m, 1525m, 1506s, 1485s, 1456m, 1418m, 1378m, 1333m, 1260s, 1238vs, 1190m, 1160m, 1126vs, 1106m, 1093m, 1037s, 1003s, 941m, 841m, 826m, 771m, 676w, 498m; ESI-MS calculated for $C_{35}H_{31}FeN_3O_8$ $m/z = 677.2$; found m/z 677.1 (M^+ , 100%), 678.1 ($M + H^+$, 50), 700.1 ($M + Na^+$, 42); R_f (HPLC) $\tau = 17.3$ min; 1H NMR (DMSO- d_6) δ 8.57 (1 H, s, $H_{\text{triazolyl}}$), 6.90 (1 H, s, H-5 or H-8), 6.71 (1 H, s, H-5 or H-8), 6.36 (1 H, d, $J = 5.2$ Hz, H-4), 6.35 (2 H, s, H-2' and H-6'), 6.04 (1 H, s, H-13), 6.01 (1 H, s, H-13), 5.32 (1 H, s, Cp), 5.29 (1 H, s, Cp), 4.77 (1 H, d, $J = 5.0$ Hz, H-1), 4.71 (2 H, br s, Cp), 4.45 (1 H, t, $J = 7.8$ Hz, H-11), 4.16 (5 H, s, Cp), 3.69 (6 H, s, 3' and 5'-OCH₃), 3.64 (3 H, s, 4'-OCH₃), 3.62 (1 H, dd, $J = 9.9, 5.1$ Hz, H-2), 3.36–3.30 (1 H, m, H-3), 3.13 (1 H, t, $J = 9.7$ Hz, H-11); $^{13}C\{^1H\}$ NMR (DMSO- d_6) 187.5 (COFc), 173.5 (C-12), 152.1 (C_{Ph}), 148.2 (C_{Ph}), 147.2 (C_{Ph}), 147.0 (C_{triazolyl}), 136.5 (C_{Ph}), 135.2 (C_{Ph}), 133.2 (C_{Ph}), 128.6 (CH_{triazolyl}), 125.6 (C_{Ph}), 109.8 (C-5 or C-8), 108.7 (C-5 or C-8), 108.1 (C-5 or C-8), 101.6 (C-13), 77.8 (C_{piso}), 72.7 (2 \times Cp), 71.0 (Cp), 70.8 (Cp), 69.9 (Cp), 67.1 (C-11), 59.9 (4'-OCH₃), 57.8 (C-4), 55.8 (3' and 5'-OCH₃), 42.9 (C-1), 40.5 (C-2), 36.4 (C-3).

4-Deoxy-4-(4-(3-ferrocenyl-3-oxoprop-1-yl)-1H-1,2,3-triazol-1-yl)-4-epipodophyllotoxin 31. This compound was synthesized in 32% yield (49 mg) according to general procedure C starting from 58 mg (0.219 mmol) of (4-pentynoyl)ferrocene. The product was purified on silica using a gradient starting from 9 : 1 to 7 : 3 of dichloromethane–ethyl acetate as the eluent. Mp > 200 °C (dec.); elemental analysis found: C, 63.0; H, 5.5; N, 6.4. $C_{37}H_{35}FeN_3O_8$ requires C, 63.0; H, 5.0; N, 6.0%; λ_{max} (ClCH₂CH₂Cl)/nm 453, 361 and 335 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 770, 1375 and 2406); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 2926m, 1780s, 1663s, 1588s, 1506s, 1485s, 1456s, 1418m, 1382m, 1332m, 1237vs, 1189m, 1160m, 1126vs, 1092m, 1036s, 1001s, 930m; ESI-MS calculated for $C_{37}H_{35}FeN_3O_8$ m/z 705.2; found m/z 705.1 (M^+ , 63%), 706.1 ($M + H^+$, 100); R_f (HPLC) $\tau = 15.7$ min. 1H NMR (DMSO- d_6) δ 7.77 (1 H, s, $H_{\text{triazolyl}}$), 6.70 (1 H, s, H-5 or H-8), 6.67 (1 H, s, H-5 or H-8), 6.32 (2 H, s, H-2' and H-6'), 6.21 (1 H, d, $J = 5.2$ Hz, H-4), 6.02 (1 H, s, H-13), 5.98 (1 H, s, H-13), 4.78 (2 H, br s, Cp), 4.73 (1 H, d, $J = 5.2$ Hz, H-1), 4.55 (2 H, br t, $J = 1.6$ Hz, Cp), 4.35 (1 H, t, $J = 8.0$ Hz, H-11), 4.15 (5 H, s, Cp), 3.67 (6 H, s, 3' and 5'-OCH₃), 3.63 (3 H, s, 4'-OCH₃), 3.46 (1 H, dd, $J = 14.7, 5.3$ Hz, H-2), 3.27–3.21 (1 H, m, H-3), 3.13 (1 H, t, $J = 7.4$ Hz, CH₂CH₂COFc), 3.12 (1 H, t, $J = 6.6$ Hz, CH₂CH₂COFc), 2.96–2.91 (3 H, m, CH₂CH₂COFc and H-11); $^{13}C\{^1H\}$ NMR (DMSO- d_6) 202.0 (CH₂CH₂COFc), 173.4 (C-12), 152.0 (C_{Ph}), 148.0 (C_{Ph}), 146.8 (C_{Ph}), 146.1 (C_{triazolyl}), 136.6 (C_{Ph}), 135.2 (C_{Ph}), 132.7 (C_{Ph}), 126.1 (C_{Ph}), 122.9 (CH_{triazolyl}), 109.7 (C-5 or C-8), 108.7 (C-5 or C-8), 108.1 (C-2' and C-6'), 101.5 (C-13), 78.7 (C_{piso}), 72.0 (Cp), 71.9 (Cp), 69.4 (Cp), 69.0 (Cp), 68.9 (Cp), 67.1 (C-11), 59.8 (4'-OCH₃), 57.1 (C-4), 55.8 (3' and 5'-OCH₃), 42.9 (C-1), 40.7 (C-2), 37.9 (CH₂CH₂COFc), 36.4 (C-3), 19.6 (CH₂CH₂COFc).

4-Deoxy-4-(4-(4-ferrocenyl-4-oxobut-1-yl)-1H-1,2,3-triazol-1-yl)-4-epipodophyllotoxin 32. This compound was synthesized in 17% yield (27 mg) according to general procedure C starting from 61 mg (0.219 mmol) of (5-hexynoyl)ferrocene. The product was purified on silica using a gradient starting from

9 : 1 to 9 : 3 of dichloromethane–ethyl acetate as the eluent. Mp 194–195 °C (dec.); elemental analysis found: C-63.1; H-6.1; N-6.1. $C_{38}H_{37}FeN_3O_8$ requires C, 63.4; H, 5.2; N, 5.8%; λ_{max} (ClCH₂CH₂Cl)/nm 453, 358 and 333 ($\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$ 901, 1786 and 2031); IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 2952s, 1781s, 1663s, 1588s, 1506s, 1485s, 1456s, 1418m, 1381m, 1332m, 1287m, 1238vs, 1189m, 1160m, 1126vs, 1106m, 1092m, 1037s, 1002s, 931m, 825m, 485m; ESI-MS calculated for $C_{38}H_{37}FeN_3O_8$ $m/z = 719.2$; found m/z 719.2 (M^+ , 37%), 720.1 ($M + H^+$, 100); R_f (HPLC) $\tau = 16.2$ min. 1H NMR (DMSO- d_6) δ 7.79 (1 H, s, $H_{\text{triazolyl}}$), 6.75 (1 H, s, H-5 or H-8), 6.68 (1 H, s, H-5 or H-8), 6.33 (2 H, s, H-2' and H-6'), 6.22 (1 H, d, $J = 5.1$ Hz, H-4), 6.03 (1 H, s, H-13), 5.99 (1 H, s, H-13), 4.74 (2 H, br s, Cp), 4.72 (1 H, d, $J = 5.2$ Hz, H-1), 4.54 (2 H, br s, Cp), 4.38 (1 H, t, $J = 7.9$ Hz, H-11), 4.19 (5 H, s, Cp), 3.68 (6 H, s, 3' and 5'-OCH₃), 3.64 (3 H, s, 4'-OCH₃), 3.51 (1 H, dd, $J = 14.8, 5.1$ Hz, H-2), 3.29–3.22 (1 H, m, H-3), 2.97 (1 H, t, $J = 9.6$ Hz, H-11), 2.78 (2 H, t, $J = 7.2$ Hz, CH₂CH₂CH₂COFc), 2.70 (2 H, t, $J = 7.3$ Hz, CH₂CH₂CH₂COFc), 1.95–1.91 (2 H, m, CH₂CH₂CH₂COFc); $^{13}C\{^1H\}$ NMR (DMSO- d_6) 203.0 (CH₂CH₂CH₂COFc), 173.5 (C-12), 152.1 (2 \times C_{Ph}), 148.0 (C_{Ph}), 146.9 (C_{triazolyl}), 146.5 (C_{triazolyl}), 136.5 (C_{Ph}), 135.2 (C_{Ph}), 132.8 (C_{Ph}), 126.2 (C_{Ph}), 122.7 (CH_{triazolyl}), 109.7 (C-5 or C-8), 108.6 (C-5 or C-8), 108.1 (C-2' and C-6'), 101.5 (C-13), 79.0 (C_{piso}), 71.9 (Cp), 69.4 (Cp), 68.9 (Cp), 67.2 (C-11), 59.9 (4'-OCH₃), 57.2 (C-4), 55.8 (3' and 5'-OCH₃), 42.9 (C-1), 40.7 (C-2), 38.0 (CH₂CH₂CH₂COFc), 36.5 (C-3), 24.5 (CH₂CH₂CH₂COFc), 23.5 (CH₂CH₂CH₂COFc).

Viability assay

Solutions of all the tested compounds were prepared freshly for every experiment and processed immediately. Stock solutions were prepared in DMSO and all compounds were added to cells to a final DMSO concentration of 0.2% (v/v), while controls were incubated with 0.2% DMSO alone. The chosen DMSO concentration was determined to be non-toxic to the cells.

The drug sensitivity of the cell lines was determined using the neutral red uptake assay.²⁹ Briefly, cells were seeded on 96-well plates at a density of 10 000 per well and 24 h later were treated with either the control or the test compound at a desired concentration. After 70 h of incubation, neutral red was added to the medium to a final concentration of 1 mM. After 2 h of incubation, the cells were washed with PBS, dissolved in 200 μL solubilisation solution (1% HOAc (v/v) in 50% EtOH (v/v)) and shaken for 10 min, until the neutral red was extracted from the cells. The absorbance was measured at 540 nm with an EnVisionMultilabel Plate Reader (PerkinElmer). The results were calculated as a percentage of the controls and the IC₅₀ values for each cell line and substance were calculated with GraphPad Prism 5.02 software (GraphPad Inc.) using four-parameter non-linear logistic regression.

Tubulin polymerization assay

The tubulin polymerization rate was determined using a fluorescence-based tubulin polymerization assay (Cytoskeleton, Inc., cat. no. BK011P) according to the manufacturer's instructions. The investigated compounds were tested over the con-



centration range 0.1–30 μM using freshly prepared DMSO stock solutions and the final DMSO concentration of 1% was kept constant across all samples. Paclitaxel was used as a positive control for tubulin polymerization and the results were compared to the solvent control (buffer + DMSO). The fluorescence was measured at 37 $^{\circ}\text{C}$ for 120 min at 355/40 nm excitation and 430/8 nm emission wavelengths using an EnVisionMultilabel Plate Reader (PerkinElmer).

Cell cycle analysis

Exponentially growing cells (100 000 cells per well seeded in 6-well plates 24 h before time 0) were treated with 10 nM of the test compound for 48 h. Cells were then harvested by trypsinisation, washed twice with ice-cold PBS and fixed in 70% ethanol. After storing the cells for at least 8 h at 4 $^{\circ}\text{C}$, they were stained with a propidium iodide staining solution (75 μM propidium iodide and 50 Kunitz units per mL of RNase A in PBS) for 30 min at 37 $^{\circ}\text{C}$. The samples were analysed on an LSRII (Becton Dickinson) instrument and cell cycle phase distributions were determined with FlowJo 7.6.1 software (FlowJo, LLC) using a built-in cell cycle analysis module (Watson pragmatic algorithm).

Investigation of cellular esterase effects on ferrocenyl esters

Roughly 20 million Hep G2 cells were harvested *via* trypsinisation and centrifuged (100g for 10 min at RT). The supernatant was removed by aspiration and the cell pellets were suspended in 1 mL of ice-cold MilliQ-quality water. The cells were placed on an ice-bath and sonicated (2 min of maximum power). The cells were inspected under a microscope and no intact cells were found in the resulting crude cell homogenate. No protease inhibitors were added to the homogenate to avoid non-specific inhibition of other hydrolases. A volume of 100 μL of crude cell extract was mixed with 100 μL of DMEM for pH stabilisation and then the investigated compound was added from the DMSO stock solution to a final concentration of 1 mM. The final concentration of DMSO in the sample was 1% v/v. The mixture was incubated at 37 $^{\circ}\text{C}$ and samples were taken after 1 h and 2 h of incubation. A volume of 100 μL of sample was mixed with 100 μL of ice-cold 10% w/v solution of TCA in water and allowed to incubate for approx. 10 min on ice to precipitate proteins. The sample was centrifuged (10 000 RPM for 10 min at RT) and the supernatant was carefully aspirated, filtered through a 0.22 μm PTFE filter and processed *via* HPLC. The DMSO extract of the protein pellet was also prepared and analysed *via* HPLC. Oregon Green diacetate was used as a positive control for esterase activity. It was completely digested after 1 h of incubation with crude cell extract.

Acknowledgements

This study was financially supported by the National Science Centre Poland (NCN) based on decision DEC-2012/05/B/ST5/00300. A. M. also acknowledges the National Science Centre Poland (NCN) for financial support (decision DEC-2012/04/A/

ST5/00609), which enabled the X-ray structural analysis of the compound.

References

- 1 M. L. King and M. M. Sullivan, *Science*, 1946, **104**, 244–245.
- 2 J. Bryan, *Biochemistry*, 1972, **11**, 2611–2616.
- 3 D. K. Kalwinsky, A. T. Look, J. Ducore and A. Fridland, *Cancer Res.*, 1983, **43**, 1592–1597.
- 4 W. Ross, T. Rowe, B. Glisson, J. Yalowich and L. Liu, *Cancer Res.*, 1984, **44**, 5857–5860.
- 5 Y. Q. Liu, J. Tian, K. Qian, X. B. Zhao, S. L. Morris-Natschke, L. Yang, X. Nan, X. Tian and K. H. Lee, *Med. Res. Rev.*, 2015, **35**, 1–62.
- 6 (a) L. Zhang, Z. Zhang, J. Wang, Y. Chen, F. Chen, Y. Lin and X. Zhu, *RSC Adv.*, 2016, **6**, 2895–2903; (b) L. Zhang, Z. Zhang, F. Chen, Y. Chen, Y. Lin and J. Wang, *Eur. J. Med. Chem.*, 2016, **123**, 226–235.
- 7 X. W. Guan, X. H. Xu, S. L. Feng, Z. B. Tang, S. W. Chen and L. Hui, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 1561–1566.
- 8 (a) A. Kamal, V. L. Nayak, C. Bagul, M. V. P. S. Vishnuvardhan and A. Mallareddy, *Apoptosis*, 2015, **20**, 1518–1529; (b) J. Y. Choi, W. G. Hong, J. H. Cho, E. M. Kim, J. Kim, C. H. Jung, S. G. Hwang, H. D. Um and J. K. Park, *Int. J. Oncol.*, 2015, **47**, 1257–1265.
- 9 D. Tierny, F. Serres, Z. Segaula, I. Bemelmans, E. Bouchaert, A. Pétain, V. Brel, S. Couffin, T. Marchal, L. Nguyen, X. Thuru, P. Ferré, N. Guilbaud and B. Gomes, *Clin. Cancer Res.*, 2015, **21**, 5314–5323.
- 10 <https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005241-20/IT>.
- 11 (a) A. Mariani, A. Bartoli, M. Atwal, K. C. Lee, C. A. Austin and R. Rodriguez, *J. Med. Chem.*, 2015, **58**, 4851–4856; (b) A. H. Banday, V. V. Kulkarni and V. J. Hruby, *MedChemComm*, 2015, **6**, 94–104.
- 12 I. Hyder, D. Yedlapudi, S. V. Kalivendi, J. Khazir, T. Ismail, N. Nalla, S. Miryala and H. M. Sampath Kumar, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 2860–2863.
- 13 G. Jaouen and M. Salmain, *Bioorganometallic Chemistry: Applications in Drug Discovery, Biocatalysis, and Imaging*, 2015.
- 14 (a) B. Pérès, R. Nasr, M. Zarioh, F. Lecerf-Schmidt, A. Di Pietro, H. Baubichon-Cortay and A. Boumendjel, *Eur. J. Med. Chem.*, 2017, **130**, 346–353; (b) J. L. Kedge, H. V. Nguyen, Z. Khan, L. Male, N. J. Hodges, S. L. Horswell, Y. Mehellou, J. H. R. Tucker and H. V. Roberts, *Eur. J. Inorg. Chem.*, 2017, **2017**, 466–476; (c) A. Wiczorek, A. Błaż, J. Zakrzewski, B. Rychlik and D. Plazuk, *ACS Med. Chem. Lett.*, 2016, **7**, 612–617; (d) A. Gross, H. Alborzinia, S. Piantavigna, L. L. Martin, S. Wölfl and N. Metzler-Nolte, *Metallomics*, 2015, **7**, 371–384; (e) D. Plazuk, B. Rychlik, A. Błaż and S. Domagała, *J. Organomet. Chem.*, 2012, **715**, 102–112; (f) J. Spencer, J. Amin, M. Wang, G. Packham, S. S. S. Alwi, G. J. Tizzard, S. J. Coles, R. M. Paranal, J. E. Bradner and T. D. Heightman, *ACS Med. Chem. Lett.*, 2011, **2**, 358–362;



- (g) E. Hillard, A. Vessi res, F. Le Bideau, D. Plazuk, D. Spera, M. Huch  and G. Jaouen, *ChemMedChem*, 2006, **1**, 551–559; (h) A. I. Guti rrez-Hern ndez, J. G. L pez-Cort s, M. C. Ortega-Alfaro, M. T. Ram rez-Apan, J. De Jes s C zares-Marinero and R. A. Toscano, *J. Med. Chem.*, 2012, **55**, 4652–4663; (i) S. Top, B. Dauer, J. Vaissermann and G. Jaouen, *J. Organomet. Chem.*, 1997, **541**, 355–361.
- 15 (a) D. Scutaru, L. Tataru, I. Mazilu, M. Vata, T. Lixandru and C. Simionescu, *Appl. Organomet. Chem.*, 1993, **7**, 225–231; (b) B. Long, C. He, Y. Yang and J. Xiang, *Eur. J. Med. Chem.*, 2010, **45**, 1181–1188; (c) M. G rmen, M. S. I. Veitia, F. Trigui, M. El Arbi and C. Ferroud, *J. Organomet. Chem.*, 2015, **794**, 274–281; (d) M. Patra, M. Wenzel, P. Prochnow, V. Pierroz, G. Gasser, J. E. Bandow and N. Metzler-Nolte, *Chem. Sci.*, 2015, **6**, 214–224.
- 16 (a) C. Biot, G. Glorian, L. A. Maciejewski, J. S. Brocard, O. Domarle, G. Blampain, P. Millet, A. J. Georges and J. Lebibi, *J. Med. Chem.*, 1997, **40**, 3715–3718; (b) C. Biot, L. Delhaes, L. A. Maciejewski, M. Mortuaire, D. Camus, D. Dive and J. S. Brocard, *Eur. J. Med. Chem.*, 2000, **35**, 707–714; (c) X. Wu, P. Wilairat and M. L. Go, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 2299–2302; (d) A. Patti, S. Pedotti, T. Grassi, A. Idolo, M. Guido and A. De Donno, *J. Organomet. Chem.*, 2012, **716**, 216–221.
- 17 M. Beaup rin, D. Polat, F. Roudesly, S. Top, A. Vessi res, J. Oble, G. Jaouen and G. Poli, *J. Organomet. Chem.*, 2017, **839**, 83–90.
- 18 (a) D. Plazuk, A. Wieczorek, A. Blauz and B. Rychlik, *MedChemComm*, 2012, **3**, 498–501; (b) A. Wieczorek, A. B lauz, A.  al, H. J. Arabshahi, J. Reynisson, C. G. Hartinger, B. Rychlik and D. Plazuk, *Chem. – Eur. J.*, 2016, **22**, 11413–11421.
- 19 J. Ren, L. Wu, W. Q. Xin, X. Chen and K. Hu, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 4778–4782.
- 20 J. C. Quirion, G. L. I. C. Deliencourt-Godefroy and C. Audouard, *Pat.*, US318675, 2009.
- 21 S. Saaby, I. Winckelmann, K. Sondergaard, X. Liang, Y. Ke, X. Wang and J. Ye, WO2010094164 A1, 2010.
- 22 K. J. Rinehart Jr., R. J. Curby Jr. and P. E. Sokol, *J. Am. Chem. Soc.*, 1957, **79**, 3420–3424.
- 23 I. Suzuki, Q. Chen, A. Ueno and T. Osa, *Bull. Chem. Soc. Jpn.*, 1993, **66**, 1472–1481.
- 24 D. Plazuk and J. Zakrzewski, *J. Organomet. Chem.*, 2009, **694**, 1802–1806.
- 25 A. Blauz and B. Rychlik, *J. Pharmacol. Toxicol. Methods*, 2017, **84**, 57–65.
- 26 M. A. Jordan and L. Wilson, *Nat. Rev. Cancer*, 2004, **4**, 253–265.
- 27 D. Plazuk and J. Zakrzewski, *Synth. Commun.*, 2004, **34**, 99–107.
- 28 H. Zeng and H. Zhang, *Eur. J. Med. Chem.*, 2014, **72**, 10–17.
- 29 G. Repetto, A. Del Peso and J. L. Zurita, *Nat. Protoc.*, 2008, **3**, 1125–1131.

